Your privacy, your choice

We use essential cookies to make sure the site can function. We also use optional cookies for advertising, personalisation of content, usage analysis, and social media.

By accepting optional cookies, you consent to the processing of your personal data - including transfers to third parties. Some third parties are outside of the European Economic Area, with varying standards of data protection.

See our privacy policy for more information on the use of your personal data.

for further information and to change your choices.

Skip to main content
Fig. 1 | Journal of Biomedical Science

Fig. 1

From: EpCAM-targeted betulinic acid analogue nanotherapy improves therapeutic efficacy and induces anti-tumorigenic immune response in colorectal cancer tumor microenvironment

Fig. 1

Particle characterization and determination of in silico mechanism of action. A Gel electrophoresis demonstrating conjugation of the aptamer to the nanoparticle. 1st well: standard DNA ladder; 2nd well: Apt-2cNP; 3rd well: free aptamer; 4th well: 2cNP. B Field emission scanning electron microscopic image of Apt-2cNP. C Transmission electron microscopic image of Apt-2cNP. D Atomic force microscopic image of Apt-2cNP. E Drug release profile of Apt-2cNP in PBS (pH 7.4), in PBS, containing 0.5% β-cyclodextrin, and in sodium acetate buffer of pH 5.5. Data shows mean ± SD (n = 3). F Molecular electrostatic potential map of BA and its analogue 2c. The blue, red, and green color indicates the most electron-deficient (hydrogen bond acceptor), -rich (hydrogen bond donor), and -neutral (hydrophobic) regions, respectively. G The change of Gibbs free energy values (kCal/mol) for the interactions of BA and 2c with topoisomerase-I (TIase I) and topoisomerase-II (TIase II) enzymes separately. H Protein pocket model representing the docking of compound 2c at the active site of topoisomerase-II. I Docking represented in a stick model (3D) shows the interaction of 2c with different amino acid residues at the active site of topoisomerase-II

Back to article page